Qual é o preço para ReNeuron Group plc (RENE)

O preço para ReNeuron Group plc (RENE) é $0.00042815

Qual é a capitalização de mercado para ReNeuron Group plc (RENE)

A capitalização de mercado para ReNeuron Group plc (RENE) é $13.55K

ReNeuron Group plc (RENE) Dividendos

Established in 1997 and headquartered in Pencoed, UK, ReNeuron Group plc focuses on the research, development, and commercialization of innovative cell-based therapies. The company is actively developing a CTX stem cell therapy candidate targeting stroke disability, which is currently at the partnering stage for distribution both within and outside China. Another significant pipeline asset is its human retinal progenitor cell therapy, now in Phase I/IIa clinical trials, designed to treat retinitis pigmentosa, a debilitating eye disease leading to blindness. Furthermore, ReNeuron is conducting pre-clinical investigations into CTX-derived exosomes, which are microscopic, information-carrying packages released by CTX cells. The firm also generates revenue through the licensing of its ReNcell products. Collaboratively, ReNeuron has partnered with University College London to explore the creation of immune cells from induced pluripotent stem cells for application in anti-cancer cell therapies.

Ano	Dividendo (ajustado para desdobramentos)	Alterar
Não há dados suficientes para as datas fornecidas.

Ano

Dividendo (ajustado para desdobramentos)

Alterar

Não há dados suficientes para as datas fornecidas.

Ano	Dividendo	Alterar
Não há dados suficientes para as datas fornecidas.

Ano

Dividendo

Alterar

Não há dados suficientes para as datas fornecidas.

Empresa	Número de pagamentos de dividendos	País
Vertex Pharmaceuticals Incorporated VRTX.US	0.00%	US
Argenx SE ARGX.US	0.00%	NL
Lonza Group AG LONN.SW	0.00%	CH
Samsung Biologics Co.,Ltd. 207940.KS	0.00%	KR
UCB S.A. UCB.BR	29.00%	BE

Empresa

Número de pagamentos de dividendos

País